Skip to content

US · LLY · DRUG MANUFACTURERS - GENERAL

Eli Lilly and Company (LLY) intrinsic value and stock valuation

$1,347.11as of 2026-11-21 · Mkt cap 1.1T

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Eli Lilly and Company DCF and intrinsic value

InvestorsCraft values LLY with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from LLY’s statements →

Eli Lilly and Company Graham Number

Graham Number: $123.61d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Indianapolis, IN 46285 lilly.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$65.2B+21.6% 5y CAGRd
20112025
Net income
$20.6B+27.2% 5y CAGRd
20112025
Free cash flow
$8.97B+14.9% 5y CAGRd
20112025
Total equity
$26.5B+35.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$65.2B$45B$34.1B$28.5B$28.3B
Operating income$29.7B$17.5B$10.8B$8.65B$7.93B
Net income$20.6B$10.6B$5.24B$6.24B$5.58B
EPSd$23M$11.7M$5.8M$6.57M$5.85M
Operating cash flow$16.8B$8.82B$4.24B$7.59B$7.37B
Capital expenditure-$-7.84B-$-8.4B-$-7.39B-$-2.99B-$-1.98B
Free cash flow$8.97B$414.3M-$-3.15B$4.6B$5.39B
Total assets$112.5B$78.7B$64B$49.5B$48.8B
Total debt$42.5B$33.6B$25.2B$16.2B$16.9B
Net debt$35.3B$30.4B$22.4B$14.2B$13.1B
Total equity$26.5B$14.3B$10.9B$10.8B$9.15B
Cash and short-term investments$7.27B$3.42B$2.93B$2.21B$3.91B
Income statement
20252024202320222021
Revenue$65.2B$45B$34.1B$28.5B$28.3B
Cost of revenue$10.6B$8.42B$7.08B$6.63B$7.31B
Gross profit$54.6B$36.6B$27B$21.9B$21B
Research and development expenses$13.3B$11B$9.31B$7.19B$6.93B
Selling, general and administrative expenses$11.1B$8.13B$6.94B$6.07B$6.14B
Other expenses$487.5M$0.00$0.00$0.00$0.00
Operating expenses$24.9B$19.1B$16.3B$13.3B$13.1B
Cost and expenses$35.5B$27.5B$23.3B$19.9B$20.4B
Interest income$153.3M$175.2M$173.6M$62.8M$25.4M
Interest expense$795.3M$780.6M$485.9M$331.6M$339.8M
Depreciation and amortization$1.56B$1.77B$1.53B$1.52B$1.55B
Ebitda$27.9B$15.2B$8.57B$8.66B$8.04B
Operating income$29.7B$17.5B$10.8B$8.65B$7.93B
Total other income/expenses, net-$-3.97B-$-4.82B-$-4.23B-$-1.85B-$-1.78B
Income before tax$25.7B$12.7B$6.55B$6.81B$6.16B
Income tax expense$5.09B$2.09B$1.31B$561.6M$573.8M
Net income$20.6B$10.6B$5.24B$6.24B$5.58B
Weighted average shares outstanding$898M$900.6M$899.4M$950.2M$953.7M
Weighted average diluted shares outstanding$898M$904.1M$903.3M$950.2M$953.7M
Balance sheet
20252024202320222021
Cash and short-term investments$7.27B$3.42B$2.93B$2.21B$3.91B
Net receivables$20.2B$13.3B$11.3B$8.56B$8.13B
Inventory$13.7B$7.59B$5.77B$4.31B$3.89B
Total current assets$55.6B$32.7B$25.7B$18B$18.5B
Property, plant and equipment, net$24.7B$17.1B$12.9B$10.1B$8.99B
Goodwill and intangible assets$12.4B$11.9B$11.8B$11.3B$11.6B
Long-term investments$2.8B$3.22B$3.05B$2.9B$3.21B
Total non-current assets$56.8B$46B$38.3B$31.5B$30.4B
Total assets$112.5B$78.7B$64B$49.5B$48.8B
Accounts payable$5.38B$3.23B$2.6B$1.93B$1.67B
Short-term debt$1.64B$5.12B$6.9B$1.5B$1.54B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$35.2B$28.4B$27.3B$17.1B$15.1B
Long-term debt$40.9B$28.5B$18.3B$14.7B$15.3B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$50.7B$36.1B$25.8B$21.6B$24.6B
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$85.9B$64.4B$53.1B$38.7B$39.7B
Common stock$590M$592.4M$593.6M$594.1M$596.3M
Retained earnings$24.5B$13.5B$10.3B$10B$8.96B
Accumulated other comprehensive income (loss)-$-2.88B-$-4.32B-$-4.33B-$-3.84B-$-4.34B
Total equity$26.5B$14.3B$10.9B$10.8B$9.15B
Total investments$2.91B$3.37B$3.16B$3.05B$3.3B
Total debt$42.5B$33.6B$25.2B$16.2B$16.9B
Net debt$35.3B$30.4B$22.4B$14.2B$13.1B
Cash flow statement
20252024202320222021
Net income$20.6B$10.6B$5.24B$6.24B$5.58B
Depreciation and amortization$2B$1.77B$1.53B$1.52B$1.55B
Stock-based compensation$626M$645.6M$628.5M$371.1M$342.8M
Change in working capital-$-8.09B-$-5.39B-$-3.06B-$-800K-$-1.01B
Accounts receivable-$-7B-$-2.16B-$-2.45B-$-299.6M-$-1.28B
Inventory-$-4.67B-$-2.51B-$-1.43B-$-599.7M-$-235.9M
Accounts payable$10.2B$2.61B$4.27B$1.33B-$-1.01B
Net cash provided by operating activities$16.8B$8.82B$4.24B$7.59B$7.37B
Investments in property, plant and equipment-$-7.84B-$-5.06B-$-3.45B-$-1.85B-$-1.31B
Acquisitions, net-$-661M-$-947.7M-$-1.04B-$-327.2M-$-747.4M
Net cash used for investing activities-$-10.97B-$-9.3B-$-7.15B-$-3.76B-$-2.87B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-4.11B-$-2.5B-$-750M-$-1.5B-$-1.25B
Dividends paid-$-5.38B-$-4.68B-$-4.07B-$-3.54B-$-3.09B
Net cash used for financing activities-$-2.21B$1.23B$3.5B-$-5.41B-$-4.13B
Net change in cash$4B$449.8M$751.6M-$-1.75B$161.4M
Cash at end of period$7.27B$3.27B$2.82B$2.07B$3.82B
Operating cash flow$16.8B$8.82B$4.24B$7.59B$7.37B
Capital expenditure-$-7.84B-$-8.4B-$-7.39B-$-2.99B-$-1.98B
Free cash flow$8.97B$414.3M-$-3.15B$4.6B$5.39B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Eli Lilly and Company

        Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

        CEO
        David A. Ricks
        Employees
        50K
        Beta
        0.51

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Eli Lilly and Company (LLY)?

        Eli Lilly and Company (LLY) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LLY undervalued?

        LLY trades at a price of $1,347.11 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.